3-Benzoyloxy-1,3,5(10)-estratrien-17-on | 2393-53-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 3-Benzoyloxy-1,3,5(10)-estratrien-17-on
• 英文别名: [(13S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] benzoate
• CAS: 2393-53-5；13403-72-0；103128-63-8
• 化学式: C₂₅H₂₆O₃
• 分子量: 374.48
• InChiKey: HKUKRSLIEVXDMS-DJYNTIJESA-N

物化性质

• 熔点：
  217-220 °C
• 沸点：
  463.47°C (rough estimate)
• 密度：
  1.0636 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] 2-METHOXYESTRADIOL DERIVATIVES AND MEDICAL USES THEREOF<br/>[FR] DÉRIVÉS DE 2-MÉTHOXYESTRADIOL ET LEURS UTILISATIONS MÉDICALES
  申请人：PASTEUR INSTITUT KOREA

  公开号：WO2021075860A1

  公开（公告）日：2021-04-22

  The present invention relates to novel 2-Methoxyestradiol derivatives and their medical use. In particular, the novel derivatives of the present invention are useful for the treatment or prevention of liver or lung fibrosis. Accordingly, the present invention also provides medical uses of the 2-Methoxyestradiol derivatives of the present invention. The present invention also provides a method of treating or preventing liver or lung fibrosis comprising administering an effective amount of the 2-Methoxyestradiol derivatives of the present invention.

  本发明涉及新颖的2-甲氧基雌二醇衍生物及其医药用途。具体来说，本发明的新颖衍生物对于治疗或预防肝脏或肺部纤维化具有用处。因此，本发明还提供了本发明的2-甲氧基雌二醇衍生物的医药用途。本发明还提供了一种治疗或预防肝脏或肺部纤维化的方法，包括给予本发明的2-甲氧基雌二醇衍生物的有效量。
• [EN] PROCESS FOR THE PREPARATION OF ESTETROL<br/>[FR] PROCÉDÉ POUR LA PRÉPARATION D'ESTÉTROL
  申请人：CRYSTAL PHARMA SAU

  公开号：WO2015040051A1

  公开（公告）日：2015-03-26

  The invention relates to a process for obtaining Estetrol or a salt or solvate thereof, the process comprising: a) reacting a compound of formula (IV) or a salt or solvate thereof, wherein R1 is a hydroxyl protecting group selected from a silyl ether, an ether, an ester, a carbamate and a carbonate, and R2 is a hydroxyl protecting group selected from an ether, with an oxidizing agent selected from OsO4 or a source of osmium tetroxide to produce Estetrol or a compound of formula (II) or a salt or solvate thereof wherein R1 is as defined previously; and b) if a compound of formula (II) is obtained in step a), deprotecting said compound to produce Estetrol.

  该发明涉及一种获取Estetrol或其盐或溶剂化合物的方法，该方法包括：a) 反应化合物式（IV）或其盐或溶剂化合物，其中R1是从硅醚、醚、酯、氨甲酸酯和碳酸酯中选择的羟基保护基，R2是从醚中选择的羟基保护基，与从OsO4或四氧化锇的来源中选择的氧化剂反应，以产生Estetrol或化合物式（II）或其盐或溶剂化合物，其中R1如前所定义；b) 如果在步骤a)中获得化合物式（II），则去保护所述化合物以产生Estetrol。
• PROCESS FOR THE PREPARATION OF ESTETROL
  申请人：Crystal Pharma, S.A.U.

  公开号：EP3046928B1

  公开（公告）日：2017-02-08
• Use of Non-Glucocorticoid Steroids for the Treatment of Muscular Dystrophy
  申请人：Meier Thomas

  公开号：US20070259837A1

  公开（公告）日：2007-11-08

  The invention relates to the therapeutic use of certain classes of steroid compounds for treatment of muscular diseases, in particular muscle diseases caused by mutations in the gene encoding for dystrophin (Duchenne Muscular Dystrophy, DMD, and Becker Muscular Dystrophy, BMD). The steroid compounds increase the levels of the dystrophin-related protein utrophin in cultured human muscle cells derived from donors affected with Duchenne Muscular Dystrophy.
• US9988417B2
  申请人：——

  公开号：US9988417B2

  公开（公告）日：2018-06-05